Wednesday, 21 August 2019 09:14 GMT
img

Global Biologics Market Is Expected To Reach US$ 580.5 Bn By 2026 | Credence Research




(MENAFN - Credence Research) The latest market report published by Credence Research, Inc. “Biologics Market By Product (Recombinant Therapeutic Proteins, Blood & Blood Components, Cellular & Gene Therapy, Vaccines), By Disease (Oncology, Autoimmune Diseases, Diabetes, Infectious Diseases, Others) - Growth, Future Prospects & Competitive Analysis, 2018 - 2026” the  biologics market was valued at US$ 254.9 Bn in 2017, and expected to reach US$ 580.5 Bn by 2026 at a CAGR of 9.5 % during the forecast period from 2018 to 2026.

Browse the full report at https://www.credenceresearch.com/report/biologics-market

Market Insights

Global biologics market exhibits remunerative growth during the forecast period from 2018 to 2026 due to presence of around 800 biologics in pipeline. The growth attributed is due to incessant expansion in product portfolio with increasing demand for biologics across the globe. Rising prevalence of chronic diseases, unremitting research and development activities and continuous investment in biologics contribute to the overall market growth. According to World Health Organization (WHO), by 2020 chronic diseases would account for 75% of deaths globally.  Cancer, autoimmune diseases, and diabetes contribute above 60% of the overall biologics market. In 2016, approximately 50% of new molecular entities approved by the FDA were biologics. Continuous development in cellular & gene therapy further catalyzes the market owing to its high efficacy and therapeutic outcome. CAR-T cell therapies are the latest therapies approved by the FDA for oncology indications.

The therapeutic expansion of biologics across various indications such as asthma, allergic conditions, dyslipidemia and other non-traditional disease areas attributed to the forecasted growth. However, the expedited expansion of biosimilars has a negative impact on the overall growth of biologics market. Biosimilars being cost-effective with similar efficacy would gain higher demand in developing countries. Biologics approved in the U.S comprise longer patent protection in comparison to those approved in Europe. Additionally, EMA has less stringent policies for biosimilars in comparison to the U.S FDA, thus North America owns larger market share than Europe and will maintain its dominance throughout the forecast period. Growing prevalence of cancer, autoimmune diseases & diabetes, presence of leading market players, and continuous research activities drive the North American market. Asia Pacific is the fastest growing market accounting to double digit CAGR during the forecast period. Expansion of international players in developing nations contribute to the biologics market growth in this region. Novartis AG wishes to launch its FDA approved treatment Kymriah in Japan. However, discussions on the pricing of the treatment in Japan is still under negotiations with Ministry of Health, and Labor & Welfare (MHLW).

Biologics entering the market contest with similar indications and with more or less similar mechanism of action. Biologics market is thus highly competitive comprising established and leading market players such as Abbvie, Inc., Amgen, Inc., AstraZeneca Plc., Celgene Corporation, Janssen Pharmaceuticals, Inc., Merck & Co. Inc., Novartis AG, Pfizer, Inc., Roche Holding AG, Sanofi S.A and Takeda Pharmaceutical Co., Ltd.

Key Market Movements:

Globally, biologics market continues to witness a lucrative growth with a CAGR of 9.5% for the period from 2018 to 2026
Presence of an extensive product portfolio and above 800 pipeline molecules, contributed to the overall growth of the market
Among all the products available, recombinant therapeutic proteins maintains dominancy comprehending larger market share during the period from 2016 to 2026
The introduction of new cellular and gene therapy namely CAR-T cell provides better therapeutic outcome. Furthermore, research activities in this area contributes to the overall market growth during the forecast period.

Download Free PDF Sample Request: https://www.credenceresearch.com/sample-request/59079

Table of Content

Chapter 1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Market Segmentation
1.3. Research Scope 
1.4. Research Methodology
1.4.1. Phase I-Secondary Research
1.4.2. Phase II-Primary Research
1.4.3. Phase III-Expert Panel Review
1.4.4. Assumptions

Chapter 2. Executive Summary
2.1. Global Biologics Market Portraiture
2.2. Global Biologics Market, by Product, 2017 (US$ Bn)
2.3. Global Biologics Market, by Disease, 2017 (US$ Bn)
2.4. Global Biologics Market, by Geography, 2017 (US$ Bn)

Chapter 3. Global Biologics Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Market Dynamics
3.2.1. Market Drivers
3.2.1.1. Growing Prevalence Of Chronic Conditions
3.2.1.2. Increased Investment in Research Activities
3.2.2. Market Challenges
3.2.2.1. Growth of Biosimilars
3.2.2.2. Challenge 2
3.2.3. Market Opportunities
3.2.3.1. Strong Pipeline Candidates
3.3. Attractive Investment Proposition, by Geography, 2017
3.4. Competitive Landscape, by Key Players, 2017

Chapter 4. Global Biologics Market, by Product, 2016-2026 (US$ Bn)
4.1. Overview
4.2. Recombinant Therapeutic Proteins
4.2.1. Monoclonal Antibodies
4.2.2. Hormones
4.2.3. Cytokines
4.2.4. Enzymes
4.3. Blood & Blood components
4.4. Cellular & Gene Therapy
4.5. Vaccines

Do Inquiry before Buying for this report at https://www.credenceresearch.com/inquiry-before-buying/59079

Chapter 5. Global Biologics Market, by Disease, 2016-2026 (US$ Bn)
5.1. Overview
5.2. Oncology
5.2.1. Breast Cancer
5.2.2. Leukemia
5.2.3. Ovarian Cancer
5.2.4. Non-Hodgkin Lymphoma
5.2.5. Prostate Cancer
5.2.6. Colorectal Cancer
5.2.7. Others (bladder cancer, lung cancer, etc.)
5.3. Autoimmune diseases
5.3.1. Systemic Sclerosis
5.3.2. Crohn’s Disease
5.3.3. Rheumatoid arthritis
5.3.4. Systemic Lupus Erythematous
5.3.5. Others (Sjogren's syndrome, multiple sclerosis, pernicious anemia, etc.)
5.4. Diabetes
5.5. Infectious diseases
5.6. Others (cardiovascular diseases, ophthalmic conditions, dermatological diseases, etc.)

Chapter 6. Global Biologics Market, by Geography, 2016-2026 (US$ Bn)
6.1. Overview
6.2. North America Biologics Market, 2016-2026 (US$ Bn)
6.2.1. North America Biologics Market, by Product, 2016-2026 (US$ Bn)
6.2.2. North America Biologics Market, by Disease, 2016-2026 (US$ Bn)
6.2.3. North America Biologics Market, by Country, 2016-2026 (US$ Bn)
6.2.3.1. U.S.
6.2.3.2. Canada
6.3. Europe Biologics Market, 2016-2026 (US$ Bn)
6.3.1. Europe Biologics Market, by Product, 2016-2026 (US$ Bn)
6.3.2. Europe Biologics Market, by Disease, 2016-2026 (US$ Bn)
6.3.3. Europe Biologics Market, by Country/Region, 2016-2026 (US$ Bn)
6.3.3.1. U.K.
6.3.3.2. Germany
6.3.3.3. Rest of Europe
6.4. Asia Pacific Biologics Market, 2016-2026 (US$ Bn)
6.4.1. Asia Pacific Biologics Market, by Product, 2016-2026 (US$ Bn)
6.4.2. Asia Pacific Biologics Market, by Disease, 2016-2026 (US$ Bn)
6.4.3. Asia Pacific Biologics Market, by Country/Region, 2016-2026 (US$ Bn)
6.4.3.1. Japan
6.4.3.2. China
6.4.3.3. Rest of Asia Pacific
6.5. Latin America Biologics Market, 2016-2026 (US$ Bn)
6.5.1. Latin America Biologics Market, by Product, 2016-2026 (US$ Bn)
6.5.2. Latin America Biologics Market, by Disease, 2016-2026 (US$ Bn)
6.5.3. Latin America Biologics Market, by Country, 2016-2026 (US$ Bn)
6.5.3.1. Brazil
6.5.3.2. Mexico
6.5.3.3. Rest of Latin America
6.6. Middle East & Africa (MEA) Biologics Market, 2016-2026 (US$ Bn)
6.6.1. Middle East & Africa (MEA) Biologics Market, by Product, 2016-2026 (US$ Bn)
6.6.2. Middle East & Africa (MEA) Biologics Market, by Disease, 2016-2026 (US$ Bn)
6.6.3. Middle East & Africa (MEA) Biologics Market, by Region, 2016-2026 (US$ Bn)
6.6.3.1. GCC
6.6.3.2. Rest of MEA

Chapter 7. Company Profiles
7.1. Merck & Co. Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. Key Developments
7.2. AbbVie, Inc.
7.3. AstraZeneca Plc. 
7.4. Amgen, Inc.
7.5. Celgene Corporation 
7.6. Bristol-Myers Squibb Co.
7.7. Eli Lilly and Company
7.8. Janssen Pharmaceuticals, Inc.
7.9. GlaxoSmithKline Plc.
7.10. Novartis AG
7.11. Pfizer, Inc.
7.12. Novo Nordisk A/S
7.13. Sanofi S.A
7.14. Roche Holding AG
7.15. Takeda Pharmaceutical Co., Ltd

Medium Blog: https://medium.com/@kumarganesh028/global-biologics-market-is-expected-to-reach-us-580-5-bn-by-2026-credence-research-cffe93a94f3a

MENAFN1807201900709442ID1098774226


Global Biologics Market Is Expected To Reach US$ 580.5 Bn By 2026 | Credence Research

Credence Research

Authors_Square_PromoteArticle_Ink2019

  Most popular stories  

Day | Week | Month